title: Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
abstract: DNA topoisomerase IIalpha (Topo IIalpha) is a molecular and immunohistochemical marker that indicates proliferation rate and is the target for several antineoplastic agents. The present immunohistochemical study of a large series of surgically removed pituitary tumors was designed to assess the prognostic significance of Topo IIalpha expression relative to patient age, gender, tumor type and size, invasiveness, metastasis, MIB-1-labeling index and angiogenesis. Changes of Topo IIalpha expression in the tumors treated with bromocriptine and octreotide, a long-acting somatostatin analogue were also investigated. Topo IIalpha immunopositivity was detected only in the nuclei of tumor cells. Gonadotroph adenomas, null cell adenomas, and ACTH-producing adenomas had the lowest Topo IIalpha indices, whereas primary pituitary carcinomas and silent type 3 adenomas presented the highest counts. The statistical study demonstrated no significant correlation between Topo IIalpha expression, patient gender, and vascularity. In contrast, significant negative correlation was found between Topo IIalpha expression and patient age. Topo IIalpha expression was significantly higher in invasive than noninvasive tumors. A tendency to have higher counts was also observed in microadenomas compared with in macroadenomas. Although Topo IIalpha and MIB-1 indices were similar in most tumor types, no significant correlation between Topo IIalpha and MIB-1-labeling indices (r =.16, P =.09) was found. Only non-functioning adenomas showed positive correlation (r =.41, P =.006) between both proliferation markers. Our results demonstrated a significant decrease in Topo IIalpha index in octreotide-treated, GH-producing adenomas, compared with untreated tumors, but no significant changes were observed in bromocriptine-treated, PRL-producing adenomas. The present study showed no significant advantage of Topo IIalpha over MIB-1 as a prognostic marker; however, Topo IIalpha may provide crucial information regarding selection of adenohypophyseal tumors responsive to antineoplastic therapy, such as invasive pituitary adenomas and pituitary carcinomas, which exhibit a high Topo IIalpha index.
authors.affiliation: Department of Anatomy, Laboratory of Histology, University of Santiago de Compostela Lugo, Spain.
authors.forename: Sergio
authors.initials: S
authors.lastname: Vidal
authors.forename: Kalman
authors.initials: K
authors.lastname: Kovacs
authors.forename: Eva
authors.initials: E
authors.lastname: Horvath
authors.forename: Fabio
authors.initials: F
authors.lastname: Rotondo
authors.forename: Takao
authors.initials: T
authors.lastname: Kuroki
authors.forename: Ricardo V
authors.initials: RV
authors.lastname: Lloyd
authors.forename: Bernd W
authors.initials: BW
authors.lastname: Scheithauer
mesh_terms: D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000032:analysis; D000951:Antigens, Neoplasm; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001808:Blood Vessels / Q000737:chemistry / Q000473:pathology; D002648:Child; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis* / Q000187:drug effects; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis
chemical_list: D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D018931:Antineoplastic Agents, Hormonal; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D004250:DNA Topoisomerases, Type II; D015282:Octreotide